PUMA BIOTECHNOLOGY, INC. PBYI
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
6/9
Piotroski F — financial health
-14.13
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $228.4M | $31.1M | — | $41.7M | $130.3M |
| 2024 | $230.5M | $30.3M | — | $38.9M | $92.1M |
| 2023 | $235.6M | $21.6M | — | $26.9M | $53.4M |
| 2022 | $228.0M | $2,000 | — | -$15.8M | $21.6M |
| 2021 | $253.2M | -$29.1M | — | $20.6M | -$2.4M |
| 2020 | $225.1M | -$60.0M | — | $727,000 | -$6.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| WILSON TROY EDWARD | director | 2026-06-12 | Sell | 10,800 | $7.20 |
| MOYES JAY M | director | 2026-06-12 | Sell | 22,000 | $7.22 |
| Senderowicz Adrian | director | 2026-06-12 | Sell | 27,000 | $7.20 |
| Dorval Allison | director | 2026-06-12 | Sell | 11,610 | $7.20 |
| Stuglik Brian M | director | 2026-06-12 | Sell | 8,100 | $7.20 |
| Dorval Allison | director | 2026-06-11 | Grant | 27,000 | — |
| Cesano Alessandra | director | 2026-06-11 | Grant | 27,000 | — |
| WILSON TROY EDWARD | director | 2026-06-11 | Grant | 27,000 | — |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -14.13 (distress)
- Working capital / assets 0.376
- Retained earnings / assets -5.935
- EBIT / assets 0.172
- Equity / liabilities 1.516
Source: SEC EDGAR filings · CIK 0001401667 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.